Boehringer’s SGLT-2 complex, Synjardy, is expected to be approved this month
The complex of the Boehringer Ingelheim’s SGLT-2-inhibitor antidiabetic agent, Jardiance(empagliflozin), and metformin will enter the domestic market this month at the fastest.
The product name of the complex will be ‘Synjardy’ and is expected to be approved on the 23rd.
Currently, the AstraZen...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
